B-vitamin Levels and Adverse Pregnancy Outcomes

Sponsor
Westlake University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05073978
Collaborator
Beijing Obstetrics and Gynecology Hospital (Other)
15,000
1
18
834.7

Study Details

Study Description

Brief Summary

This prospective case-control study aims to examine the effects of blood vitamin B levels in first-trimester pregnant women on the pregnancy outcomes

Detailed Description

Folate deficiency can cause severe adverse pregnancy outcomes, such as neural tube defects. Effective folate functioning requires essential metabolic interactions with other B vitamins including vitamin B2, vitamin B3, vitamin B6, and vitamin B12, which can also influence pregnancy outcomes independently. For example, animal and family studies have identified that niacin (B3) deficiency can lead to congenital malformations. However, how folate and related B-vitamin levels interact with each other while affecting various pregnancy outcomes including abortion, birth defects, pregnancy complications, etc. is unclear. Besides, folate levels in previous studies were mostly measured in plasma which are easily influenced by dietary factors, instead of red blood cell folate which can reflect the long-term status. Moreover, the difference in the risk of neural tube defects across a range of maternal red blood cell folate concentrations has been largely ignored. Using data of pregnant women recruited at Beijing Obstetrics and Gynecology Hospital from December 2020 to December 2021, this case-control study aims to examine the association of folate and related B-vitamin levels in first-trimester blood samples (plasma and red blood cell) with pregnancy outcomes, particularly the association between niacin deficiency and birth defects.

Study Design

Study Type:
Observational
Anticipated Enrollment :
15000 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
The Association Between Niacin Deficiency and Birth Defects: a Case-control Study
Actual Study Start Date :
Dec 1, 2020
Anticipated Primary Completion Date :
Jun 1, 2022
Anticipated Study Completion Date :
Jun 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Case group

Case group with certain pregnancy outcome, e.g., abortion, stillbirth, preterm birth, and birth defects,gestational hypertension, gestational diabetes mellitus, etc.

Other: No intervention
This is an observational study without any intervention

Control group

Control group without certain pregnancy outcome,e.g., abortion, stillbirth, preterm birth, and birth defects,gestational hypertension, gestational diabetes mellitus, etc.

Other: No intervention
This is an observational study without any intervention

Outcome Measures

Primary Outcome Measures

  1. fetal outcomes [at delivery]

    Including intrauterine growth retardation,abortion, stillbirth, preterm birth, live birth

  2. fetal outcomes [42 days after delivery]

    Including birth defects

  3. maternal outcomes [at delivery]

    Including gestational hypertension, preeclampsia, gestational diabetes mellitus, hypothyroidism

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 45 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Pregnant women with 6-13(+6 days) gestational weeks

  • Resided in Beijing in the past year

  • Pregnant women who intend to have antenatal examinations and delivery at Beijing Obstetrics and Gynecology Hospital

  • Pregnant women who are willing to participate in this study with informed consent

Exclusion Criteria:
  • Women with Hepatitis B, syphilis, HIV/AIDS and other infectious diseases.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Beijing Obstetrics and Gynecology Hospital Beijing Beijing China 100020

Sponsors and Collaborators

  • Westlake University
  • Beijing Obstetrics and Gynecology Hospital

Investigators

  • Principal Investigator: Hongjun Shi, PhD, Westlake University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Westlake University
ClinicalTrials.gov Identifier:
NCT05073978
Other Study ID Numbers:
  • 20210119SHJ001
First Posted:
Oct 12, 2021
Last Update Posted:
Oct 12, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Westlake University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 12, 2021